Overview

Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of the addition of prednisolone to conventional initial treatment (intravenous immunoglobulin [IVIG] plus aspirin) in reducing coronary artery lesion in children with Kawasaki disease (KD) .
Phase:
Phase 3
Details
Lead Sponsor:
Children's Hospital of Fudan University
Collaborators:
Beijing Children's Hospital
Chengdu Women's and Children's Central Hospital
Children's Hospital of Chongqing Medical University
Children's Hospital Of Soochow University
First People's Hospital of Hangzhou
Inner Mongolia People's Hospital
Jiangxi Province Children's Hospital
Qilu Hospital of Shandong University
Shengjing Hospital
Sichuan Provincial People's Hospital
The First Hospital of Jilin University
Third Affiliated Hospital of Zhengzhou University
Wuhan Union Hospital, China
Yuying Children's Hospital of Wenzhou Medical University
Treatments:
Aspirin
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Rho(D) Immune Globulin